清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.

医学 化疗 内科学 养生 肿瘤科 临床终点 化疗方案 食管癌 不利影响 随机对照试验 外科 癌症
作者
Renquan Zhang,De sheng Song,Wei Liu,Long Yao,A. Chen,Wei Ge,Shao hui Hu,Jian Chen,Yun long Huang,Jun rui Xun
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 4064-4064 被引量:7
标识
DOI:10.1200/jco.2023.41.16_suppl.4064
摘要

4064 Background: Camrelizumab combined with chemotherapy has a very ideal therapeutic effect and low toxicity in the treatment of solid tumors. camrelizumab plays an important role in the treatment of locally advanced esophageal squamous cell carcinoma. Methods: This study is a prospective, multicenter, randomized controlled study. Inclusion criteria were patients aged 18-75 years with an ECOG score of 0-1 who had not received other treatments previously and had histologically confirmed resectable locally advanced esophageal squamous cell carcinoma (clinical stages cT1-4N1-3M0 and cT3-4N0M0). Patients received camrelizumab combined with chemotherapy (albumin paclitaxel + cisplatin in chemotherapy regimen) or chemotherapy alone (albumin paclitaxel + cisplatin in chemotherapy regimen). The primary endpoints are pathological complete remission (pCR) rate and 5-year overall survival (OS). Secondary endpoints including disease-free survival rate, duration of drug treatment and adverse events and we attempt to explore the correlation between drug efficacy and PD-L1 expression. The target sample size was 400 and patients were divided into two groups according to a 1:1 ratio who were received camrelizumab plus chemotherapy and chemotherapy alone. Results: From January 2021 to October 2022, 243 patients with resectable locally advanced esophageal squamous cell carcinoma from four centers were enrolled. Of these, 205 (85.2%) were male and 38 (15.6%) were female. Median age was 65 years. Most patients (182, 74.9%) were in clinical stage III and had an ECOG score of 1 (185, 76.1%). 150 patients had completed all clinical trial cycles and the result showed that among 90 patients who received camrelizumab plus chemotherapy, 25 patients achieved pathological complete remission(pCR), 39 achieved major partial remission (MPR), 11 had stable disease and 1 had progressive disease, with a pCR rate of 27.8% and MPR rate of 43.3%. Among 60 patients who received chemotherapy alone, 6 patients achieved pCR, 13 patients achieved MPR, 19 patients had stable disease and 2 patients had progressive disease, with a pCR rate of 10.0% and MPR rate of 26.7%. The most common adverse events were reactive cutaneous capillary endothelial proliferation (72.1%), nausea (42%), and leukopenia (15.5%), all of which were in grade 1 – 2 with manageable safety. Conclusions: Preliminary results of this study showed that the overall efficacy of camrelizumab plus chemotherapy was better than that of chemotherapy alone and the drug was safe and reliable. In future work, we will continue to analyze the survival outcomes, drug safety and the relationship between drug efficacy and PD-L1 expression and other biomarkers. Clinical trial information: ChiCTR2000040330 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被11采纳,获得10
13秒前
wcl完成签到,获得积分10
18秒前
YZY完成签到 ,获得积分10
32秒前
flb1227完成签到 ,获得积分10
40秒前
蔡勇强完成签到 ,获得积分10
45秒前
RRui完成签到,获得积分10
51秒前
alei089完成签到 ,获得积分10
1分钟前
Benhnhk21完成签到,获得积分10
1分钟前
vbnn完成签到 ,获得积分10
1分钟前
1分钟前
俊逸蛋挞完成签到 ,获得积分10
1分钟前
奔跑的应助被姚老表采纳,获得30
1分钟前
有志者发布了新的文献求助20
1分钟前
眯眯眼的安雁完成签到 ,获得积分10
1分钟前
阿申爱乐的应助被Benhnhk21采纳,获得30
1分钟前
Agatha完成签到 ,获得积分10
1分钟前
cadcae完成签到,获得积分10
1分钟前
有志者完成签到,获得积分10
1分钟前
风中可仁完成签到 ,获得积分10
1分钟前
文若完成签到,获得积分10
1分钟前
奔跑的应助被qin采纳,获得10
1分钟前
1分钟前
leng发布了新的文献求助10
2分钟前
小白白完成签到 ,获得积分10
2分钟前
2分钟前
木子完成签到 ,获得积分10
2分钟前
阿申爱乐的应助被Benhnhk21采纳,获得30
2分钟前
虚拟的白云完成签到,获得积分10
2分钟前
qin发布了新的文献求助10
2分钟前
45度科研狗完成签到 ,获得积分10
2分钟前
Jack_20708124完成签到 ,获得积分10
3分钟前
阿申爱乐的应助被Benhnhk21采纳,获得30
3分钟前
ikutovaya完成签到,获得积分10
3分钟前
atra2107完成签到 ,获得积分10
3分钟前
zhangguo完成签到 ,获得积分10
3分钟前
3分钟前
楚楚完成签到 ,获得积分0
3分钟前
3分钟前
脑洞疼的应助被义气的导师采纳,获得10
4分钟前
56633985完成签到 ,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195230
求助须知:如何正确求助?哪些是违规求助? 9580992
关于积分的说明 21873110
捐赠科研通 7795292
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484708